From the Journals
The overall response rate was 90% in previously untreated patients who received the highest dose.
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
GLASGOW – A study comparing whole-genome sequencing (WGS) with fluorescence in situ hybridization showed that the WGS was reliable and clinically...
HOUSTON – Acute lymphoblastic leukemia patients with measurable residual disease (MRD) negativity prior to...
HOUSTON – Haplo-HSCT outperforms chemotherapy for the treatment of adults with ALL in first complete response, particularly MRD-positive patients...
Dasatinib will be available in tablet form and as a powder for oral suspension.
SAN DIEGO – The combination appears to bolster CAR T-cell effects and persistence in children with relapsed B-ALL.
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
The approval was based on data from the phase 2 BLAST trial.
The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.